Zacks Downgrades Alexza Pharmaceuticals to Neutral

December 8, 2011 11:26 AM | 7 seconds read |
Zacks Investment Research has downgraded Alexza Pharmaceuticals ALXA from Outperform to Neutral and has established a $1.50 price target.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: DowngradesPrice TargetAnalyst RatingsZacks investment research
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!